ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia

This study has been completed.

Sponsored by: Sandoz Inc.
Information provided by: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier: NCT00002007
  Purpose

To evaluate the safety of repeated courses of sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF ) administered subcutaneously to patients with HIV infection and leukopenia. To determine if administration of GM-CSF will prevent some or all of the hematologic toxicity associated with zidovudine ( AZT ) treatment in patients with pre-existing leukopenia. To assess any clinical and/or virologic benefits from administering alternating weeks of GM-CSF and AZT to patients with symptomatic HIV infection who have a history of cytologically confirmed Pneumocystis carinii pneumonia ( PCP ) or a circulating absolute CD4 lymphocyte count less than 200 cells/mm3.


Condition Intervention
HIV Infections
Cytopenias
Drug: Zidovudine
Drug: Sargramostim

MedlinePlus related topics:   AIDS   

Drug Information available for:   Zidovudine    Sargramostim    Granulocyte-macrophage colony-stimulating factor   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Dose Comparison
Official Title:   A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia
  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria

Patients must have:

  • Serum antibody to HIV with or without evidence of HIV antigenemia.
  • White blood cells (WBC) = or < 4500 cells/mm3 measured on at least 2 occasions separated by a minimum of 1 week.
  • Qualifying indications for AZT therapy.
  • Life expectancy = or > 6 months.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Current or past history of malignancy including Kaposi's sarcoma.
  • Excessive diarrhea or significant malabsorption.
  • If patients have had > 10 percent weight loss within the past 3 months, they should not have malabsorption as evidenced by serum carotene < 75 IU/ml, serum vitamin A < 75 IU/ml, significant malabsorption 4 foul-smelling or greasy stools per day or other criteria.
  • Currently hospitalized or hospitalized within the last 4 weeks for the treatment of opportunistic infection (IO).
  • Less than 1 week since completing treatment of Pneumocystis carinii pneumonia (PCP).
  • Active OI requiring systemic treatment.
  • Evidence of nutritional deficiencies that may contribute to anemia and/or leukopenia.

Concurrent Medication:

Excluded within 4 weeks of study entry:

  • Zidovudine (AZT).
  • Other antiviral agent associated with leukopenia.
  • Investigational drug.
  • Immunomodulators.
  • Interferon.
  • Steroids.
  • Excluded within 8 weeks of study entry:
  • Ribavirin.
  • Excluded within 4 months of study entry:
  • Suramin.

Patients with the following are excluded:

  • Current or past history of malignancy including Kaposi's sarcoma.
  • Excessive diarrhea or significant malabsorption.
  • Currently hospitalized or hospitalized within the last 4 weeks for the treatment of opportunistic infection (OI).
  • Less than 1 week since completing treatment of Pneumocystis carinii pneumonia (PCP).
  • Evidence of nutritional deficiencies that may contribute to anemia and/or leukopenia.

Prior Medication:

Excluded:

  • Prophylactic therapy for Pneumocystis carinii pneumonia (PCP) that may cause leukopenia.

Risk Behavior:

Excluded:

  • Current drug or alcohol abusers.
  • Unprotected sexual contact or other activities that may result in reinfection with HIV.

Patients must be willing to refrain from unprotected sexual contact or other activities that may result in reinfection with HIV.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002007

Locations
United States, Maryland
Natl Cancer Institute    
      Bethesda, Maryland, United States, 20892

Sponsors and Collaborators
Sandoz Inc.
  More Information


Study ID Numbers:   067C, 202
First Received:   November 2, 1999
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00002007
Health Authority:   United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:
Leukopenia  
Granulocyte-Macrophage Colony-Stimulating Factor  
Acquired Immunodeficiency Syndrome  
Zidovudine  

Study placed in the following topic categories:
Virus Diseases
Sexually Transmitted Diseases, Viral
Hematologic Diseases
HIV Infections
Sexually Transmitted Diseases
Acquired Immunodeficiency Syndrome
Zidovudine
Leukocyte Disorders
Leukopenia
Retroviridae Infections
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:
Antimetabolites
Anti-Infective Agents
Communicable Diseases
RNA Virus Infections
Anti-HIV Agents
Slow Virus Diseases
Immune System Diseases
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Infection
Antiviral Agents
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Anti-Retroviral Agents
Therapeutic Uses
Lentivirus Infections
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on November 30, 2008




Links to all studies - primarily for crawlers